Canaccord Raises Mind Medicine’s Price Target To $2.00 Following Financing

This morning, Canaccord Genuity raised its 12-month price target on Mind Medicine (NEO: MMED) from C$1.75 to C$2.00 while reiterating its speculative buy rating after the company closed its C$28.8 million financing. The financing saw the issuing of 27.4 million units, with each unit consisting of one common share and one half warrant at C$1.05 per unit.

Mind Medicine is expected to allocate the proceeds to a number of different initiatives, including:

  • $14.3 million to its four core development programs (18-MC for OUD and LSD for ADHD, anxiety, and cluster headaches)
  • $2.3 million to discovery
  • $3.3 million to general corporate purposes and working capital

Tania Gonsalves, Canaccord’s analyst, says that they are, “taking our R&D estimates up.” As last month during their roadshow, management guided that the 2021 budget is $30-$40 million, which is higher than the $25 million forecasted by Canaccord. She says that knowing the $14.3 million spent on its core programs is in line with its $15.3 million estimate, they are merely adding $10 million to research and development costs for preclinical and discovery work.

The main reason for the price target increase is, “MMED’s ending fully diluted share count is lower than anticipated. Together, this has the effect of increasing our target price from $1.75/ sh to C$2.00/sh.” Canaccord prior forecast was under the assumption that Mind Medicine would have had to raise at $0.31 per share versus the $1.05 per unit that they actually managed to conduct the financing at.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

2 Responses

  1. Since Mindmef has applied for uplisting on the Nasdaq can you detail the implications for the IPO price and date? Typically 6 weeks if a longer time which we are now approaching. Thanks so much.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

Giant Mining Encounters Native Copper As Hole MHB-34 Hits 563 Metres Depth

Verses Hits Commercialization Stage With Genius AI Platform

Related News

Kinross: BMO Views Revised Russian Asset Sale As Positive, Despite Halving Of Sales Figure

On June 15th, Kinross Gold Corporation (TSX: K) announced that it had completed its sale...

Saturday, June 18, 2022, 03:12:00 PM

Mindmed: Eight Capital Resumes Coverage With $6.50 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes...

Friday, September 17, 2021, 03:23:00 PM

Xebec Adsorption: Canaccord Lifts Price Target To $6

On July 6th, Xebec Adsorption (TSX: XBC) announced a master service agreement with a leading...

Thursday, July 8, 2021, 03:27:00 PM

Beyond Meat Sees Analysts Slash Price Targets

Beyond Meat, Inc. (Nasdaq: BYND) recently reported its third quarter results for the period ending...

Sunday, November 20, 2022, 11:12:00 AM

Village Farms: Raymond James Speculates On Acquisition By Canopy Growth

This morning, Raymond James sent out a note to investors giving a scenario analysis where...

Thursday, December 24, 2020, 12:18:23 PM